BP-DBS for dystonia-choreoathetosis cerebral palsy

The Lancet Neurology

Volumn 8, Issue 8, 2009, Pages 692-693

  Berweck, Steffen ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; ETIRACETAM; TETRABENAZINE; TRIHEXYPHENIDYL;

BRAIN DEPTH STIMULATION; CEREBRAL PALSY; CHOREOATHETOSIS; CLINICAL DECISION MAKING; DISEASE SEVERITY; DYSTONIA; HUMAN; LETTER; PATIENT SELECTION; PRIORITY JOURNAL;

ATHETOSIS; CEREBRAL PALSY; CHOREA; DEEP BRAIN STIMULATION; DYSTONIA; GLOBUS PALLIDUS; HUMANS;

EID: 67650096878     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(09)70172-3     Document Type: Letter

References (4)

1. Rosenbaum P., Paneth N., Leviton A., et al. A report: the definition and classification of cerebral palsy April 2006. Dev Med Child Neurol 109 suppl (2007) 8-14
2. Surveillance of cerebral palsy in Europe (SCPE). Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Dev Med Child Neurol 42 (2000) 816-824
3. Vidailhet M., Yelnik J., Lagrange C., et al. Bilateral pallidal deep brain stimulation for the treatment of patients with dystonia-choreoathetosis cerebral palsy: a prospective pilot study. Lancet Neurol (2009) 10.1016/S1474-4422(09)70151-6 published online July 2.
4. Sanger T.D., Bastian A., Brunstrom J., et al. Prospective open-label clinical trial of trihexyphenidyl in children with secondary dystonia due to cerebral palsy. J Child Neurol 22 (2007) 530-537